Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I

  title={Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I},
  author={H. H. Guldner and Carin Szostecki and Hans Peter Vosberg and H. J. Lakomek and Edward Penner and Friedlinde A. Bautz},
Sera of patients suffering from the autoimmune disease progressive systemic sclerosis (PSS) are known to contain autoantibodies which have been reported to recognize a 70 kDa antigenic protein, designated the Scl 70 antigen. By immunoblotting of nuclear extracts from HeLa cells with sera from scleroderma patients we observed that the size of the antigen present in such cells depends on the conditions of antigen isolation. When protease inhibitors were included in the extraction buffer, a 95 kDa… 
Antinuclear autoantibodies: probes for defining proteolytic events associated with apoptosis
The use of ANAs as probes for defining proteolytic events associated with apoptosis promises to yield important insights into the mechanisms driving this cell death pathway.
A protein fragment derived from DNA-topoisomerase I as a novel tumour-associated antigen for the detection of early stage carcinoma
The findings in this study suggest that the autoantibody against the novel TAA may be a potential biomarker for use in the early detection and diagnosis of cancer.
Autoantigen components recognizable by scleroderma sera are exported via ectocytosis of fibroblasts.
The results suggest that ectocytosis might be one of the potential pathways for cells to export intracellular antigens and subsequently cause autoimmune reactions.
Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera
The 90-kDa nucleolus organizer region autoantigen (NOR-90) was previously shown to be identical to the human upstream binding factor (hUBF) and composed of twoMr forms and these two populations were recognized by human autoantibodies.
Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
This is the first report establishing that AFAs in SSc are strongly correlated with anti- topo I and, furthermore, that anti-topo I antibodies themselves display AFA activity by reacting with determinants at the fibroblast surface.
Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion
The combined presence of both marker autoantibodies in systemic scleroderma is therefore not as rare as previously reported and may predict severe disease.
Challenges and Controversies in Autoantibodies Associated with Systemic Rheumatic Diseases
Since the first identification of self-reactive antibodies in systemic lupus erythematosus and other systemic autoimmune rheumatic diseases, many autoantibodies have been identified as useful probes
Investigation of DNA topoisomerase I as an autoantigen at the thyroid cancer
A possible linkage between the autoimmune processes and malignization of the thyroid gland cells is suggested, as well as the enzyme physico-chemical properties and its immunoreactivity in the ELISA and immunoblotting.


Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma.
A protein antigenic to antibodies from scleroderma patients was isolated from rat liver nuclei using a combination of biochemical and immunologic methods and the result indicated that these antibodies are effectively monospecific for Scl-70.
A soluble acidic protein of the cell nucleus which reacts with serum from patients with systemic lupus erythermatosus and Sjögren's syndrome.
A soluble nuclear antigen that reacts with sera obtained from patients with systemic lupus erythematosus and Sjögren's syndrome has been described and was shown to react with specific antibodies by precipitin, complement fixation, and immunofluorescence techniques.
Scl-86, a marker antigen for diffuse scleroderma.
The results are consistent with the idea that Scl-70 is a degradation product of SCl-86, and screening of patients' serum for this antibody might predict the development of diffuse scleroderma.
Human anti-centromere sera recognise a 19.5 kD non-histone chromosomal protein from HeLa cells.
Immunoblotting experiments with a protein fraction enriched in HeLa chromosomal proteins revealed that the antigenic target common to all 18 sera is a polypeptide of 19.5 kD, which is not one of the core histones, and is not soluble under conditions which favour the release of nuclear ribonucleoprotein particles.
Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases.
It is likely that the patient with hemagglutinating antibodies to ribonuclease-resistant extractable nuclear antigen has mixed connective-tissue disease, if the serum contains only ribonucleoprotein antibody in high titer.
Identification of human Sm and (U1) RNP antigens by immunoblotting.
Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus.
  • M. Lerner, J. Steitz
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1979
It is argued that each of the six snRNAs exists in a separate small nuclear ribonucleoprotein (snRNP) complex with a total molecular weight of about 175,000.
Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.
Three types of antibodies appeared to be highly specific for scleroderma: antibody to Scl-70 antigen, antibody to centromere, and antinucleolar antibody, and the anti-centromere antibody appeared to been highly selective for the CREST variant of progressive systemic sclerosis.
Autoantibody to centromere (kinetochore) in scleroderma sera.
The autoantibody was present in high frequency in the calcinosis/Raynaud's phenomenon/esophageal dysmotility/sclerodactyly/telangiectasia variant of scleroderma and appeared to be a protein or polypeptide tightly bound to DNA.